3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
36
Colonic Neoplasms
10
Rectal Neoplasms
8
Neoplasm Metastasis
8
Neoplasms
5
Pancreatic Neoplasms
2
Carcinoma, Neuroendocrine
2
Adenocarcinoma
2
Stomach Neoplasms
1
Ras-mutated Metastatic Colorectal Cancer
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Metastatic Colorectal Adenocarcinoma
1
Liver Metastasis Colon Cancer
1
Gastrointestinal Neoplasms
1
Exanthema
1
Carcinoma, Basal Cell
1
Carcinoma
1
CRC
1
Advanced Cancer
1
Interventions
Fulvestrant
2
ruxolitinib
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Gels
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Exanthema
×
IFL protocol
×
Clear all
NCT00332163
2016-02-23
STEPP
Amgen
Phase 2
Completed
95 enrolled
23 charts